ReviewBiomedical engineering online2026
AI-integrated nanomaterial-based biosensors for biomedical diagnostics: engineering design, signal processing, and clinical translation.
Review in Biomedical engineering online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanobiosensor platforms based on nanomaterials have the potential to change the future of biomedical diagnostics with highly sensitive detection as well as quick responses and various functionalities. This review article will systematically outline the design principles, signal transduction mechanisms, and the biomedical use of nanobiosensors with a strong focus on including AI and wearable technologies to achieve these benefits. Examples of nanomaterials (organic and inorganic, as well as hybrid), including metallic nanoparticles, graphene derivatives, quantum dots, and polymer nanocomposites, allow nanobiosensors to provide increased biosensor performance using mechanisms such as electrochemical transduction, surface plasmon resonance, Förster resonance energy transfer, and surface enhanced Raman scattering. These mechanisms make it possible to detect biomarkers with incredible sensitivity for many different types of diseases, such as all types of infection, cancer, and metabolic disorders. Furthermore, when nanobiosensors are combined with AI and IoT applications, they provide a means of processing data in real time, utilizing predictive analytics and monitoring health based on individualized care. While significant progress has been made over the past decade, barriers to translation remain, including scaling up manufacturing capacity, achieving consistent, reproducible results, validating effectiveness in clinical settings, and obtaining FDA approval for use. This review article will compare various types of biosensing platforms and their respective strengths and limitations; discuss the current challenges faced in developing these platforms; and define future areas of focus for research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.